TEMPE, Ariz., Dec. 13, 2010 (GLOBE NEWSWIRE) — Capstone Therapeutics (Nasdaq:CAPS) (the “Company”) announced today twelve-month results from its two AZX100 Phase 2a pilot clinical trials in keloid scarring and seven-month interim results of its ongoing AZX100 Phase 2a pilot clinical trial in surgical (trocar site) scarring.
The goals of a Phase 2a clinical trial include [...] http://bit.ly/ewjJlh
No comments:
Post a Comment